CN101111257A - 增加脑血流量的方法 - Google Patents

增加脑血流量的方法 Download PDF

Info

Publication number
CN101111257A
CN101111257A CNA2005800459632A CN200580045963A CN101111257A CN 101111257 A CN101111257 A CN 101111257A CN A2005800459632 A CNA2005800459632 A CN A2005800459632A CN 200580045963 A CN200580045963 A CN 200580045963A CN 101111257 A CN101111257 A CN 101111257A
Authority
CN
China
Prior art keywords
seq
blood flow
aminoacid sequence
inhibitor
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800459632A
Other languages
English (en)
Chinese (zh)
Inventor
R·布赖特
D·莫切里-罗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN101111257A publication Critical patent/CN101111257A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2005800459632A 2005-01-04 2005-12-23 增加脑血流量的方法 Pending CN101111257A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64141305P 2005-01-04 2005-01-04
US60/641,413 2005-01-04

Publications (1)

Publication Number Publication Date
CN101111257A true CN101111257A (zh) 2008-01-23

Family

ID=36692699

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800459632A Pending CN101111257A (zh) 2005-01-04 2005-12-23 增加脑血流量的方法

Country Status (8)

Country Link
US (2) US7563772B2 (https=)
EP (1) EP1846016A2 (https=)
JP (1) JP2008526750A (https=)
KR (1) KR20070103009A (https=)
CN (1) CN101111257A (https=)
AU (1) AU2005325128A1 (https=)
CA (1) CA2592500A1 (https=)
WO (1) WO2006078421A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US20070066526A1 (en) * 2005-09-02 2007-03-22 Daria Mochly-Rosen Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
WO2008097563A1 (en) * 2007-02-06 2008-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor
CA2698013A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
US20130274651A1 (en) 2012-04-16 2013-10-17 Denise Barbut System and method for improving outcome of cerebral ischemia

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1993007294A1 (en) * 1991-10-01 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Service A method of identifying ligands and antagonists of ligands
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US6255057B1 (en) * 1996-07-26 2001-07-03 Ernest Gallo Clinic And Research Center Detection of cellular exposure to ethanol
WO1998017299A1 (en) * 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
WO2001028550A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001028543A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
US20020048582A1 (en) * 2000-07-18 2002-04-25 King George L. Methods of modulating angiogenesis
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030134774A1 (en) * 2001-06-15 2003-07-17 Steinberg Susan F. Methods for inhibiting cardiac disorders
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
JP4567296B2 (ja) * 2003-03-11 2010-10-20 株式会社リコー 電子写真の画像位置検出方法およびこれを用いた記録装置
US20050164324A1 (en) * 2003-06-04 2005-07-28 Gygi Steven P. Systems, methods and kits for characterizing phosphoproteomes
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow

Also Published As

Publication number Publication date
US7563772B2 (en) 2009-07-21
EP1846016A2 (en) 2007-10-24
US20090270328A1 (en) 2009-10-29
CA2592500A1 (en) 2006-07-27
WO2006078421A2 (en) 2006-07-27
WO2006078421A3 (en) 2007-03-22
AU2005325128A1 (en) 2006-07-27
KR20070103009A (ko) 2007-10-22
JP2008526750A (ja) 2008-07-24
US8492348B2 (en) 2013-07-23
US20060148702A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US8492348B2 (en) Methods of increasing cerebral blood flow
JP7143374B2 (ja) 虚血のための組み合わせ療法
JP7209364B2 (ja) 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2022012924A (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
JP4592772B2 (ja) δＰＫＣの活性化および阻害のためのペプチド
JP6741642B2 (ja) くも膜下出血および虚血の治療法
JP2009542611A (ja) アルファ−シヌクレイン凝集の阻害
JP2002502594A (ja) 神経保護ペプチドおよびその使用
CN104837485A (zh) 血管紧张素在治疗脑部病况中的用途
KR101110758B1 (ko) 뇌졸중 표적용 펩티드 및 이의 용도
US20070066526A1 (en) Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
KR102415717B1 (ko) 혈액뇌장벽 투과능을 가지는 신규한 펩타이드 및 이의 용도
US20090186814A1 (en) Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US6372713B1 (en) Anti-depressant effects of corticotropin release inhibiting factor
US20090048174A1 (en) Methods for inhibiting angiogenesis and tumor growth by inhibition of beta or delta protein kinase C
HK1240123A1 (en) Method for preventing or treating liver damage and associated diseases
HK40003366A (en) Combination therapy for ischemia
US20050239703A1 (en) Anticancer peptide compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080123